New dual-action cancer-killing virus

November 19, 2018, Medical Research Council
A human colorectal adenocarcinoma showing the fibroblasts (brown) surrounding the cancer cells (blue), protecting them from the immune system. Credit: Human Protein Atlas (ACTA2)

Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

It is the first time that cancer-associated fibroblasts within solid tumours - that are tricked into protecting the cancer from the and supplying it with growth factors and nutrients - have been specifically targeted in this way.

The researchers, who were primarily funded by the Medical Research Council (MRC) and Cancer Research UK, say that if further safety testing is successful, the dual-action - which they have tested in human cancer samples and in mice - could be tested in humans with carcinomas as early as next year.

Currently, any therapy that kills the 'tricked' may also kill fibroblasts throughout the body - for example in the bone marrow and skin - causing toxicity.

In this study, published in the journal Cancer Research, the researchers used a virus called enadenotucirev, which is already in clinical trials for treating carcinomas. It has been bred to infect only cancer cells, leaving healthy cells alone.

They added genetic instructions into the virus that caused infected cancer cells to produce a protein called a bispecific T-cell engager.

Cancer cells and nearby fibroblasts being killed (the bright green flashes) by the virus enadenotucirev equipped with a bispecific T-cell engager.The cancer cells (not colored - black) are infected by the virus and actively secrete the bispecific T-cell engager, before dying. The T-cell engager causes the T cells (small, round and blue) to attach to the fibroblasts (red) and kill them. Credit: J Freedman/Cancer Research

The protein was designed to bind to two types of cells and stick them together. In this case, one end was targeted to bind to fibroblasts. The other end specifically stuck to T cells - a type of immune cell that is responsible for killing defective cells. This triggered the T cells to kill the attached fibroblasts.

Dr Joshua Freedman, from the Department of Oncology at the University of Oxford, who was first author on the study said: "We hijacked the virus's machinery so the T-cell engager would be made only in infected cancer cells and nowhere else in the body. The T-cell engager molecule is so powerful that it can activate immune cells inside the tumour, which are being supressed by the cancer, to attack the fibroblasts."

Dr Kerry Fisher, from the Department of Oncology at the University of Oxford, who led the research said: "Even when most of the cancer cells in a carcinoma are killed, fibroblasts can protect the residual cancer cells and help them to recover and flourish. Until now, there has not been any way to kill both cancer cells and the fibroblasts protecting them at the same time, without harming the rest of the body.

"Our new technique to simultaneously target the fibroblasts while killing with the virus could be an important step towards reducing immune system suppression within carcinomas and should kick-start the normal immune process.

"These viruses are already undergoing trials in people, so we hope our modified virus will be moving towards clinical trials as early as next year to find out if it is safe and effective in people with cancer."

The time-lapse video shows cancer cells (not coloured -- black) turning bright green as they are killed by the virus. The fibroblasts (red) are unaffected. Credit: J Freedman/Cancer Research

The scientists successfully tested the therapy on fresh human cancer samples collected from consenting patients, including solid prostate cancer tumours which reflect the complex make-up of real tumours. They also tested the virus on samples of healthy human bone marrow and found it did not cause toxicity or inappropriate T cell activation.

Dr Nathan Richardson, head of molecular and cellular medicine at the MRC said: "Immunotherapy is emerging as an exciting new approach to treating cancers. This innovative viral delivery system, which targets both the cancer and surrounding protective tissue, could improve outcomes for patients whose cancers are resistant to current treatments. Further clinical studies will be crucial to determine that the stimulation of the patient's immune system does not produce unintended consequences".

Dr Michelle Lockley, Cancer Research UK's expert on immunotherapy, said: "Using the power of the body's own immune system to tackle cancer is a growing area of research. This work in human tumour samples is encouraging, but can be complicated - one of the biggest challenges of immunotherapies is predicting how well they will work with the patient's immune system, and understanding what the side effects could be. The next stage will be using to test whether this is both a safe and effective way to treat the disease in people."

The virus targets carcinomas, which are the most common type of cancer and start in cells in the skin or in tissues that line or cover internal organs, such as the pancreas, colon, lungs, breasts, ovaries and prostate.

'Simultaneously targeting and immunosuppressive stromal cells using an oncolytic virus expressing a T-cell engager' by Freedman J et al is published in Cancer Research.

Explore further: Tumour immune cells could aid cancer therapies, study shows

More information: Cancer Research (2018). cancerres.aacrjournals.org/con … 008-5472.CAN-18-1750

Related Stories

Tumour immune cells could aid cancer therapies, study shows

November 7, 2018
A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests.

Viruses show new promise in treating cancer

September 13, 2018
Viruses have shown renewed promise in the treatment of cancer, after new research has shown they retain their cancer-killing ability even when injected into the bloodstream.

New cancer vaccine platform a potential tool for tailored and efficacious targeted cancer therapy

October 5, 2018
Researchers at the University of Helsinki have reported PeptiENV, a cancer vaccine platform that can be used to improve the therapeutic efficacy of oncolytic enveloped viruses currently in clinical use. With the help of this ...

A simple blood test provides personalised therapy for cancer patients

September 6, 2018
Researchers have developed a simple blood test that can select cancer patients where therapies that use the body's own immune system (immunotherapies) are more likely to be effective.

Virus could help treat advanced cancers

June 12, 2018
Early results from a small-scale clinical trial have revealed the potential of a virus to treat some advanced cancers.

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Inflammatory bowel disease linked to prostate cancer

December 7, 2018
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Duude
not rated yet Nov 22, 2018
Cancer cells turning green as they are killed. That's the kind of shoot-em up video I adore.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.